A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Status:
Terminated
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities
(any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2 dose
(RP2D) and preliminary clinical activity of duvortuxizumab when administered intravenously to
participants with relapsed or refractory B-cell malignancies [diffuse-large B cell lymphoma
(DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), chronic lymphocytic leukemia
(CLL), and acute lymphoblastic leukemia (ALL)].